Dermatitis News

BOSTON — Patients with eczema are increasingly turning to over-the-counter cannabinoid products and physicians should be ready to discuss their benefits, according to a poster presented at the American Academy of Dermatology Annual Meeting.

Infants born during the COVID-19 lockdown in Ireland between March and May 2020 experienced higher rates of atopic dermatitis and egg sensitization, but not egg allergy, according to a study published in Pediatric Allergy and Immunology.

Atopic dermatitis patients treated with lebrikizumab and topical steroids experienced improvement in disease severity, itch and quality of life, Eli Lilly announced in a press release.

Patients taking dupilumab for atopic dermatitis who developed COVID-19 had lower levels of antibodies and milder symptoms than patients on other treatments, according to a study published in Annals of Allergy, Asthma & Immunology.

BOSTON — In this video, Arcutis Chief Medical Officer Patrick Burnett, MD, PhD, gives an update on the company’s clinical trials of roflumilast at the American Academy of Dermatology Annual Meeting.

BOSTON — In this video, Sanofi Head of Global Development, Immunology and Inflammation Naimish Patel, MD, discusses research regarding dupilumab (Dupixent, Sanofi/Regeneron) presented at the American Academy of Dermatology Annual Meeting.

BOSTON — Atopic dermatitis patients treated with an oral CCR4 inhibitor showed improvement in disease severity, as well as down-regulation of AD genes, according to a study presented at the American Academy of Dermatology Annual Meeting.

BOSTON — Pruritus and atopic dermatitis-related gene expression were altered after treatment with difelikefalin, according to a study presented at the American Academy of Dermatology Annual Meeting.

BOSTON — Chronic spontaneous urticaria has a negative impact on patients’ lives, including on both mental and physical health and daily activities, according to a poster presented at the American Academy of Dermatology Annual Meeting.

BOSTON — Roflumilast foam 0.3% was efficacious in improving itch and quality of life in seborrheic dermatitis patients, according to a poster presented at the AAD annual meeting.